Download - Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research
![Page 1: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/1.jpg)
Children’s HospitalInformatics Program
HarvardMedical School
INDIVO as a Personally-Controlled Research Platform for Chronic Disease Registries Research
Marc D. Natter, MDProject Manager, CARRAnet Informatics Development CoreFellow, Intelligent Health Lab
Kenneth D. Mandl, MD MPHPI & Director, CARRAnet Informatics Development CoreDirector, Intelligent Health Lab
Intelligent Health Lab & Children’s Hospital Informatics Program, Children’s Hospital BostonCenter for Biomedical Informatics, Harvard Medical School
June 18, 2012
![Page 2: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/2.jpg)
Going ‘Retro’:
Translating Research into Improved Care through Registries• Cystic Fibrosis Foundation
– LeRoy Matthews, Warren Warwick, Don Berwick, and others
Left: Gawande A, The Bell Curve. New Yorker Magazine 12/2004Right: http://www.nytimes.com/2009/12/22/health/22cyst.html
![Page 3: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/3.jpg)
The Pediatric Oncology Story:Protocol-Based Care, 1981-1991
Sources: 1. Wagner HP, et al. Childhood NHL in Switzerland: incidence and survival of 120 study and 42 non-study patients. Med Pediatr Oncol. 1995 May; 24(5):279-80.2. Sharon Murphy, Pediatric Oncology Group, personal communication
• Patients enrolled on SPOG/POG Protocol: Survival = 76%, N=120• Patients not enrolled in study: Survival = 52%, N = 42
![Page 4: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/4.jpg)
NCI; $801.4
NCCDPHP; $707.9
NIA; $378.9
NHLBI; $243.3
NIMH; $202.4
NIDDK; $188.0
NIAMS; $157.1
NIAAA; $139.6
NIAID; $82.0
NINDS; $81.7
NIDA; $29.8
NCBDD; $28.3NCRR; $24.9
NIDCD; $19.3 NIDCR; $16.4 ATSDR; $16.0 NICHD; $12.7 NIEHS; $9.9NIGMS; $9.3
NIOSH; $7.5NCPDCID; $2.1
NIBIB; $1.6NEI; $1.2
NLM; $0.5
FIC; $0.1
NIH & CDC Registry-related Project Funding:FY 2009 active projects by Institute or Center(cumulative since 1992, in millions, FY 2008
CPI-adjusted dollars)
*NIH grants & contracts: FY 1992-2009; CDC grants & contracts: FY 1995-2009
ATSDR: Agency for Toxic Substances & Dis-ease RegistryFIC: Fogarty International CenterNCBBB: Nat'l Center on Birth Defects & De-velopmental DisabilitiesNCCDPDP: Nat'l Center for Chronic Disease Prevention & Health PromotionNCI: National Cancer InstituteNCPDCID: Nat'l Center for Preparedness, Detection, & Control of Infectious DiseasesNCRR: Nat'l Center for Research ResourcesNEI: National Eye InstituteNHLBI: Nat'l Heart, Lung, & Blood InstituteNIA: National Institute on AgingNIAAA: Nat'l Inst on Alcohol Abuse & Alco-holismNIAID: Nat'l Institute of Allergy & Infectious DiseasesNIAMS: Nat'l Institute of Arthritis & Muscu-loskeletal & Skin DiseasesNIBIB: Nat'l Institute of Biomedical Imaging & BioengineeringNICHD: Nat'l Institute of Child Health & Hu-man DevelopmentNIDA: Nat'l Institute on Drug AbuseNIDCD: Nat'l Institute on Deafness & Other Communication DisordersNIDCR: Nat'l Institute of Dental & Craniofa-cial ResearchNIDDK: Nat'l Institute of Diabetes & Digestive & Kidney DisesesNIEHS: Nat'l Institute of Environmental Health SciencesNIGMS: Nat'l Institute of General Medical SciencesNIMH: Nat'l Institute of Mental HealthNINDS: Nat'l Institute of Neurological Disor-ders & StrokeNIOSH: Nat'l Institute for Occupational Safety & HealthNLM: National Library of Medicine
Grand Total: $3.162 Billion
![Page 5: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/5.jpg)
Registries and Reasons: Juvenile Idiopathic Arthritis & Risk for Eye Disease
![Page 6: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/6.jpg)
CARRAnet Grand Opportunities Grant National Registry
NIAMS RC2AR058934, Sites=56, Current Enrollment>7,000 (Target 20K)
![Page 7: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/7.jpg)
CARRAnet: Building ‘Grass Roots’ Access to Subspecialty Research Data
Common Data Set
Enhanced Data Set
Study BStudy A
Study CModular Data Sets,Shared Ontologies
Software as a Service model: server farm provides a SHRINE self-scaling, connected, but private i2b2 ‘cloud’
Data In InForm electronic data capture using standardized forms (for
now) InForm using custom forms (add-on studies) – near future Import study data (raw data files plus data mappings –
spreadsheets, databases, etc) – on the horizon
![Page 8: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/8.jpg)
CARRAnet Researcher Portal
![Page 9: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/9.jpg)
Children’s HospitalInformatics Program
HarvardMedical School
Still in Search of a System that is:
–Convenient for data input: • Patients and research subjects, not just for investigators• Online consenting for studies
–Manages personal health information for research
–Returns data to research subjects and consented 3rd parties
![Page 10: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/10.jpg)
Children’s HospitalInformatics Program
HarvardMedical School
Incorporating Patient-Reported Outcomes(NLM R01 – Mandl, Weitzman, Natter)
10
![Page 11: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/11.jpg)
Children’s HospitalInformatics Program
HarvardMedical School
Contact and Personally-identifying Information Management
– Provides a Unique Identifier for all subjects across all CARRA/CARRAnet studies
– Data under site control– Web-based, centrally hosted– Based on INDIVO
• Fine-grained permissions for patient, guardians, family members, care providers, etc
• Subjects can directly enter and update their own data• SMArt, ‘research app’ based approach
![Page 12: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/12.jpg)
Children’s HospitalInformatics Program
HarvardMedical School
Use Cases:Juvenile Arthritis + Eye Disease Registries Collaboration
• Inception cohort of 650 children with JIA followed for 5 years
• Technical aims:– Subjects enter and manage contact info– Match subjects across two different
registries without exchanging contact or personally identifying info
– Data exchange between registries– Introduce ‘low-cost’ consent process
![Page 13: Indivo as a Personally-Controlled Research Platform for Chronic Disease Registries Research](https://reader035.vdocuments.us/reader035/viewer/2022062709/558d1d7fd8b42a73258b4735/html5/thumbnails/13.jpg)
New Registry Applications,under Development
• M-CM Network: Patient-advocate initiated registry for an especially rare disease
• FDA Reporting App: 3rd party reporting from patient registries
• Ad-hoc Adverse Events Reporting: Post-marketing surveillance studies
• Consensus Treatment Plan Adherence Tool: Collaborative patient-physician views